X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa Sells 74,773 Shares

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock opened at $0.49 on Tuesday. The stock has a market cap of $83.84 million, a price-to-earnings ratio of -5.46 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a 12-month low of $0.26 and a 12-month high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The business’s 50-day simple moving average is $0.55 and its 200 day simple moving average is $0.61.

Analyst Upgrades and Downgrades

XFOR has been the topic of several research reports. Stifel Nicolaus reduced their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Rhumbline Advisers lifted its holdings in X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after buying an additional 23,831 shares during the period. Verition Fund Management LLC bought a new stake in shares of X4 Pharmaceuticals during the 3rd quarter valued at $30,000. XTX Topco Ltd lifted its stake in shares of X4 Pharmaceuticals by 41.7% in the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock valued at $106,000 after purchasing an additional 46,397 shares during the period. SG Americas Securities LLC bought a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth $37,000. Finally, Point72 Asset Management L.P. grew its stake in shares of X4 Pharmaceuticals by 15.1% during the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock worth $418,000 after purchasing an additional 81,968 shares during the period. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.